Takeda Joins Hands with BIRAC in a Groundbreaking Move for Healthcare Innovation in India

In a groundbreaking collaboration, Takeda, a global pharmaceutical giant, has inked a significant three-year Memorandum of Understanding (MoU) with the Biotechnology Industry Research Assistance Council (BIRAC) in India. This local-to-global initiative aims to propel healthcare innovation and technological advancements, providing holistic solutions to address the diverse healthcare needs.

New Delhi, Delhi, India - Takeda's commitment goes beyond the traditional realms of pharmaceuticals, reaching out to support healthcare startups and contribute to India's ambitious goal of becoming a US$300 billion Bio-economy by 2030.

The signing of the MoU was graced by the presence of Dr. Jitendra Singh, Hon’ble Union Minister of State for Science & Technology, Minister of State for the Prime Minister Office, Government of India, along with other esteemed government and industry leaders.

Takeda's role in this partnership extends beyond financial support. The pharmaceutical giant will provide crucial advisory and mentoring support to budding innovators and entrepreneurs, guiding them from the inception of ideas to the deployment of cutting-edge healthcare solutions. This aligns seamlessly with BIRAC’s vision, aiming to stimulate and enhance the research and innovation capabilities of India's biotech industry to create affordable products that cater to the masses.

Sanjay Patel, Global Head of Data Digital and Technology Innovation Capability Solutions, Takeda Pharmaceuticals International AG, shared his thoughts, "India is a vibrant and promising healthcare market. The country’s healthcare segment offers an incredible opportunity both for innovation and growth. The entrepreneurial spirit of domestic healthcare startups has the power to drive healthcare advancements not only in India but globally. This partnership between Takeda and BIRAC, thus, moves beyond convention, signifying a promise to further healthcare in a manner that sets the stage for lasting improvements in the years to come.”

Serina Fischer, General Manager, Takeda Biopharmaceuticals India Pvt. Ltd. emphasized, “At Takeda, we are committed to meeting the unmet needs of patients by discovering and delivering life-transforming treatments and innovative solutions. Our vision and mission align with the Indian Government’s aspiration for local solutions to global healthcare challenges. This partnership serves as a practical blueprint, highlighting how public and private players can join forces to propel substantial and enduring advances in healthcare.”

Ruchi Sogarwal, Head of Corporate Affairs, Takeda Biopharmaceuticals India Pvt. Ltd., added, “Collaborations between the government, academia, and industry contribute immensely to accelerating innovation and building disruptive healthcare technology solutions for addressing unmet patient needs. Our partnership with BIRAC will allow us to foster innovations, nurturing capabilities, and enhancing global competitiveness, translating bioscience into bioeconomy.”

This strategic partnership announcement took place at the Global Bio-India (GBI) 2023 event, a mega international congregation of biotechnology stakeholders. This includes international bodies, regulatory bodies, Central and State Ministries, SMEs, large industries, bioclusters, research institutes, investors, and the startup ecosystem, organized by the Department of Biotechnology (DBT), Ministry of Science & Technology, Government of India.

Takeda's move signifies a paradigm shift in the healthcare landscape, where industry giants actively participate in fostering innovation, providing a beacon of hope for transformative changes in healthcare accessibility and affordability. The collaboration is not just a business deal; it's a commitment to the well-being of communities and a testament to the potential of public-private partnerships in shaping the future of healthcare. (Ref: mycsrindia)